Watchmaker Genomics today announced the launch of TAPS+, a next-generation technology that unites genetic and epigenetic ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting results this Thursday after market hours. Here’s what investors ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

“PacBio’s mission is to enable the promise of genomics to better human health,” said Christian Henry, President and Chief Executive Officer of PacBio. “China’s regulatory approval of Sequel II CNDx ...

SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and ...

Q3 2025 Management View Eric Lefkofsky, Co-Founder, CEO, President & Chairman, opened by highlighting that "Q3 was a great quarter all around. Our Genomics volume came in super strong with 33% overall ...

Key opportunities in the AI clinical genomics interpretation market include the rising demand for precision medicine, wider adoption of AI-powered tools, advancements in predictive analytics, ...

According to a filing with the Securities and Exchange Commission dated October 8, 2025, Lancaster Investment Management ...

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...

One in four adults over the age of 25 will have a stroke in a lifetime, according to the Global Stroke Fact Sheet 2025.

First study to evaluate HER2DX in a randomized trial focused exclusively on older individuals (aged 70-80 years). HER2DX independently predicts long-term survival outcomes in patients treated ...